TATVA Overzicht aandelen
Tatva Chintan Pharma Chem Limited houdt zich bezig met de productie en verkoop van speciale chemicaliën in India en internationaal.
| Sneeuwvlok Score | |
|---|---|
| Waardering | 0/6 |
| Toekomstige groei | 5/6 |
| Prestaties in het verleden | 1/6 |
| Financiële gezondheid | 6/6 |
| Dividenden | 1/6 |
Tatva Chintan Pharma Chem Limited Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | ₹876.60 |
| 52 Week Hoogtepunt | ₹1,650.85 |
| 52 Week Laag | ₹788.50 |
| Bèta | 0.0091 |
| 11 maand verandering | -13.11% |
| 3 maanden verandering | -8.48% |
| 1 Jaar Verandering | -39.87% |
| 33 jaar verandering | -68.19% |
| 5 jaar verandering | n/a |
| Verandering sinds IPO | -62.09% |
Recent nieuws en updates
Tatva Chintan Pharma Chem Limited's (NSE:TATVA) Price In Tune With Revenues
Sep 26
Tatva Chintan Pharma Chem (NSE:TATVA) Has Affirmed Its Dividend Of ₹2.00
Aug 29Recent updates
Tatva Chintan Pharma Chem Limited's (NSE:TATVA) Price In Tune With Revenues
Sep 26Tatva Chintan Pharma Chem (NSE:TATVA) Has Affirmed Its Dividend Of ₹2.00
Aug 29Earnings Report: Tatva Chintan Pharma Chem Limited Missed Revenue Estimates By 33%
Jul 27Weak Statutory Earnings May Not Tell The Whole Story For Tatva Chintan Pharma Chem (NSE:TATVA)
May 11Tatva Chintan Pharma Chem Limited's (NSE:TATVA) Share Price Matching Investor Opinion
Apr 04These Analysts Just Made A Notable Downgrade To Their Tatva Chintan Pharma Chem Limited (NSE:TATVA) EPS Forecasts
Jan 26Tatva Chintan Pharma Chem Limited (NSE:TATVA) Analysts Are Reducing Their Forecasts For This Year
May 10Tatva Chintan Pharma Chem Limited Just Missed Revenue By 15%: Here's What Analysts Think Will Happen Next
Jul 28Getting In Cheap On Tatva Chintan Pharma Chem Limited (NSE:TATVA) Is Unlikely
Jun 17Investors Shouldn't Be Too Comfortable With Tatva Chintan Pharma Chem's (NSE:TATVA) Robust Earnings
May 03Are Investors Undervaluing Tatva Chintan Pharma Chem Limited (NSE:TATVA) By 45%?
Dec 06Rendement voor aandeelhouders
| TATVA | IN Chemicals | IN Markt | |
|---|---|---|---|
| 7D | 7.1% | 3.2% | 1.8% |
| 1Y | -39.9% | 22.8% | 36.8% |
Rendement versus industrie: TATVA underperformed the Indian Chemicals industry which returned 24% over the past year.
Rendement versus markt: TATVA underperformed the Indian Market which returned 37.9% over the past year.
Prijsvolatiliteit
| TATVA volatility | |
|---|---|
| TATVA Average Weekly Movement | 5.6% |
| Chemicals Industry Average Movement | 5.9% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in IN Market | 9.4% |
| 10% least volatile stocks in IN Market | 4.0% |
Stabiele aandelenkoers: TATVA has not had significant price volatility in the past 3 months compared to the Indian market.
Volatiliteit in de loop van de tijd: TATVA's weekly volatility (6%) has been stable over the past year.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 1996 | 689 | Chintan Shah | www.tatvachintan.com |
Tatva Chintan Pharma Chem Limited houdt zich bezig met de productie en verkoop van speciale chemicaliën in India en internationaal. Het biedt een portfolio van structuurrichters voor zeolietsynthese; katalysatoren voor faseoverdracht; elektrolytzouten voor supercondensatoren en zinkionbatterijen; en farmaceutische en agrochemische producten, en andere speciale chemicaliën in de vorm van tussenproducten, ontsmettingsmiddelen, katalysatoren en oplosmiddelen. Het bedrijf levert aan de auto-, raffinage-, farmaceutische, agrochemische, verf- en coatings, kleurstoffen en pigmenten, persoonlijke verzorging en geur- en smaakstoffenindustrie.
Tatva Chintan Pharma Chem Limited Samenvatting
| TATVA fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | ₹20.51b |
| Inkomsten(TTM) | ₹176.14m |
| Inkomsten(TTM) | ₹3.71b |
116.4x
Koers/Winstverhouding5.5x
P/S-verhoudingIs TATVA overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| TATVA resultatenrekening (TTM) | |
|---|---|
| Inkomsten | ₹3.71b |
| Kosten van inkomsten | ₹1.87b |
| Brutowinst | ₹1.84b |
| Overige uitgaven | ₹1.66b |
| Inkomsten | ₹176.14m |
Laatst gerapporteerde inkomsten
Sep 30, 2024
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | 7.53 |
| Brutomarge | 49.56% |
| Nettowinstmarge | 4.74% |
| Schuld/Eigen Vermogen Verhouding | 2.1% |
Hoe presteerde TATVA op de lange termijn?
Bekijk historische prestaties en vergelijking